Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Oyster Point Pharma Inc
(NQ:
OYST
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EST, Dec 30, 2022
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Oyster Point Pharma Inc
OYSTER POINT INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Oyster Point Pharma, Inc. - OYST
December 07, 2022
From
Kahn Swick & Foti, LLC
Via
Business Wire
Oyster Point Pharma, Inc., Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 02, 2022
From
Oyster Point Pharma, Inc.
Via
GlobeNewswire
Oyster Point Pharma Reports Third Quarter 2022 Financial Results and Recent Business Highlights
November 10, 2022
From
Oyster Point Pharma, Inc.
Via
GlobeNewswire
OYSTER POINT INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Oyster Point Pharma, Inc. - OYST
November 08, 2022
From
Kahn Swick & Foti, LLC
Via
Business Wire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations:) Oyster Point Pharma, Inc. (Nasdaq - OYST), Benefitfocus, Inc. (Nasdaq - BNFT), Abiomed, Inc. (Nasdaq - ABMD), Atlas Corp. (NYSE - ATCO)
November 08, 2022
From
Brodsky & Smith LLC
Via
GlobeNewswire
Oyster Point Pharma (NASDAQ: OYST) Enters Into Agreement to be Acquired by Viatris (NASDAQ: VTRS) For $11 Per Share Plus CVR Up to $2.00 Per Share
November 07, 2022
Oyster Point Pharma, Inc. (NASDAQ: OYST) is engaged as a commercial-stage biopharmaceutical company, which is focused on the research, development
Via
Spotlight Growth
OYST Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Oyster Point Pharma, Inc. Is Fair to Shareholders
November 07, 2022
From
Halper Sadeh LLC
Via
Business Wire
Oyster Point Pharma, a Leading Ophthalmology-Focused Biopharmaceutical Company, to be Acquired by Viatris
November 07, 2022
From
Oyster Point Pharma, Inc.
Via
GlobeNewswire
Oyster Point Pharma To Report Third Quarter 2022 Financial Results On November 10, 2022
November 02, 2022
Conference Call and Webcast Scheduled for November 10, 2022, 4:30 p.m. ET
From
Oyster Point Pharma, Inc.
Via
GlobeNewswire
Oyster Point Pharma, Inc., Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 02, 2022
From
Oyster Point Pharma, Inc.
Via
GlobeNewswire
Oyster Point Pharma, Inc., Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 04, 2022
From
Oyster Point Pharma, Inc.
Via
GlobeNewswire
Oyster Point Pharma Announces Expanded Patient Access to TYRVAYA®
July 27, 2022
From
Oyster Point Pharma, Inc.
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.